Press Releases


Media Contact:
Stephen Majors
Head of Global Communications
smajors@alliancerm.org


Media Contact:
Stephen Majors
Head of Global Communications
smajors@alliancerm.org

ARM's Statement on the EU's Health Technology Assessment Guideline

March 25, 2024

Brussels, BE

The EU Health Technology Assessment (HTA) Coordination Group’s ‘Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons’ is discouraging news for rare disease patients and the Advanced Therapy Medicinal Products (ATMP) sector.


ARM welcomes the release of the Center for Medicare and Medicaid Innovation’s (CMMI) Cell and Gene Therapy Access Model

January 31, 2024

Washington, DC

The voluntary model recognizes that transformative, durable, and potentially curative gene therapies require innovative thinking about access, payment, and healthcare delivery.


FDA Approves First Gene Therapies for Sickle Cell Disease, Including First-Ever CRISPR Gene-Editing Therapy

December 8, 2023

Washington, DC

Today, the FDA approved two gene therapies to treat sickle cell disease, marking the biggest day in the history of gene therapy and a seminal moment in the history of biotechnology and human health.


New Analysis by Tufts’ NEWDIGS Shows that Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates than Other Treatments

October 11, 2023

Carlsbad, CA

New analysis shows that durable cell and gene therapies have clinical success rates between two and three times higher than other types of treatments.